113 related articles for article (PubMed ID: 2497282)
1. Demonstration of the increase in serine esterase-positive T cells in hairy-cell leukemia patients undergoing alpha-interferon therapy.
Wagner L; Goldstone AH; Worman CP
Leukemia; 1989 May; 3(5):373-9. PubMed ID: 2497282
[TBL] [Abstract][Full Text] [Related]
2. The beneficial effects of alpha-interferon in hairy cell leukemia are not attributable to NK cell-mediated cytotoxicity.
Griffiths SD; Cawley JC
Leukemia; 1987 Apr; 1(4):372-6. PubMed ID: 3669763
[TBL] [Abstract][Full Text] [Related]
3. Effect of alpha-interferon on the immune system of patients with hairy cell leukemia.
Foa R; Fierro MT; Lusso P; Bonferroni M; Raspadori D; Buzzi M; Zinzani PL; Resegotti L; Lauria F
Leukemia; 1987 Apr; 1(4):377-9. PubMed ID: 3499543
[TBL] [Abstract][Full Text] [Related]
4. Studies on the optimal dose and the mode of action of alpha-interferon in the treatment of hairy cell leukemia.
Huber C; Aulitzky W; Tilg H; von Lüttichau I; Troppmair J; Nachbauer K; Gastl G
Leukemia; 1987 Apr; 1(4):355-7. PubMed ID: 3669762
[TBL] [Abstract][Full Text] [Related]
5. B-cell growth factor-induced and alpha-interferon-inhibited proliferation of hairy cells coincides with modulation of cell surface antigens.
Gamliel H; Brownstein BH; Gurfel D; Wu SH; Rosner MC; Golomb HM
Cancer Res; 1990 Jul; 50(13):4111-20. PubMed ID: 2354460
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic and functional characterization of the circulating NK compartment in hairy cell leukaemia.
Foa R; Lauria F; Lusso P; Raspadori D; Fierro MT; Tazzari PL; Caudana L; Matera L
Clin Exp Immunol; 1986 May; 64(2):392-8. PubMed ID: 3742880
[TBL] [Abstract][Full Text] [Related]
7. Natural killer lymphocytes in hairy cell leukemia: presence of phenotypically identifiable cells with defective functional activity.
Smith BR; Rosenthal DS; Ault KA
Exp Hematol; 1985 Mar; 13(3):189-93. PubMed ID: 3884356
[TBL] [Abstract][Full Text] [Related]
8. IFN-beta induced biochemical and immunological modifications in hairy cell leukemia patients.
Liberati AM; Schippa M; Portuesi MG; Grazia Proietti M; De Angelis V; Ferrajoli A; Cinieri S; Di Clemente F; Palmisano L; Berruto P
Haematologica; 1991; 76(5):375-82. PubMed ID: 1806440
[TBL] [Abstract][Full Text] [Related]
9. Alpha-interferon and lymphokine-activated killer cells in hairy cell leukemia.
Griffiths SD; Cawley JC
Leukemia; 1988 Jun; 2(6):377-81. PubMed ID: 3374170
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of soluble CD8 antigen and interleukin-2 receptor antigen in patients with hairy cell leukemia, relationship with splenectomy and with clinical response to therapy.
Ho AD; Grossmann M; Knauf W; Martin H; Trümper L; Zwingers T; Sonnen R; Pralle H; Hunstein W
Leukemia; 1989 Oct; 3(10):718-23. PubMed ID: 2506398
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms accounting for the defective natural killer activity in patients with hairy cell leukemia.
Trentin L; Zambello R; Agostini C; Ambrosetti A; Chisesi T; Raimondi R; Bulian P; Pizzolo G; Semenzato G
Blood; 1990 Apr; 75(7):1525-30. PubMed ID: 2317560
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
[TBL] [Abstract][Full Text] [Related]
13. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
[TBL] [Abstract][Full Text] [Related]
14. Hematologic and immunologic changes in hairy cell leukemia patients treated with alpha interferon.
Turhan AG; Eaves CJ; Connors JM; Eaves AC; Karim KA; Silver KB
J Biol Regul Homeost Agents; 1988; 2(4):157-65. PubMed ID: 2907963
[TBL] [Abstract][Full Text] [Related]
15. Immunological recovery and dose evaluation in IFN-alpha treatment of hairy cell leukemia: analysis of leukocyte differentiation antigens, NK and 2',5'-oligoadenylate synthetase activity.
Nielsen B; Hokland M; Justesen J; Hasselbalch H; Ellegaard J; Hokland P
Eur J Haematol; 1989 Jan; 42(1):50-9. PubMed ID: 2914594
[TBL] [Abstract][Full Text] [Related]
16. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones.
van de Griend RJ; Ronteltap CP; Gravekamp C; Monnikendam D; Bolhuis RL
J Immunol; 1986 Mar; 136(5):1700-7. PubMed ID: 3005399
[TBL] [Abstract][Full Text] [Related]
17. Production of interferon and tumour necrosis factor by cloned human natural cytotoxic lymphocytes and T cells.
Christmas SE; Meager A; Moore M
Clin Exp Immunol; 1987 Aug; 69(2):441-50. PubMed ID: 2443292
[TBL] [Abstract][Full Text] [Related]
18. Combination treatment of 2-chlorodeoxyadenosine and type I interferon on hairy cell leukemia-like cells: cytotoxic effect and MHC-unrestricted killer cell regulation.
Reiter Z; Tomson S; Ozes ON; Taylor MW
Blood; 1993 Apr; 81(7):1699-708. PubMed ID: 8096405
[TBL] [Abstract][Full Text] [Related]
19. Systemic administration of human leukocyte interferon to melanoma patients. III. Increased helper:suppressor cell ratios in melanoma patients during interferon treatment.
Karavodin LM; Golub SH
Nat Immun Cell Growth Regul; 1983-1984; 3(4):193-202. PubMed ID: 6241293
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of cell-mediated cytotoxicity at the single cell level. VI. Direct assessment of the cytotoxic potential of human peripheral blood non-lytic effector-target cell conjugates.
Bonavida B; Lebow LT; Bradley TP
J Immunol; 1984 Feb; 132(2):594-8. PubMed ID: 6606675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
